BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

481 related articles for article (PubMed ID: 30055645)

  • 21. FAK controls the mechanical activation of YAP, a transcriptional regulator required for durotaxis.
    Lachowski D; Cortes E; Robinson B; Rice A; Rombouts K; Del Río Hernández AE
    FASEB J; 2018 Feb; 32(2):1099-1107. PubMed ID: 29070586
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serum deprivation inhibits the transcriptional co-activator YAP and cell growth via phosphorylation of the 130-kDa isoform of Angiomotin by the LATS1/2 protein kinases.
    Adler JJ; Johnson DE; Heller BL; Bringman LR; Ranahan WP; Conwell MD; Sun Y; Hudmon A; Wells CD
    Proc Natl Acad Sci U S A; 2013 Oct; 110(43):17368-73. PubMed ID: 24101513
    [TBL] [Abstract][Full Text] [Related]  

  • 23. RARγ Downregulation Contributes to Colorectal Tumorigenesis and Metastasis by Derepressing the Hippo-Yap Pathway.
    Guo PD; Lu XX; Gan WJ; Li XM; He XS; Zhang S; Ji QH; Zhou F; Cao Y; Wang JR; Li JM; Wu H
    Cancer Res; 2016 Jul; 76(13):3813-25. PubMed ID: 27325643
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Src Inhibits the Hippo Tumor Suppressor Pathway through Tyrosine Phosphorylation of Lats1.
    Si Y; Ji X; Cao X; Dai X; Xu L; Zhao H; Guo X; Yan H; Zhang H; Zhu C; Zhou Q; Tang M; Xia Z; Li L; Cong YS; Ye S; Liang T; Feng XH; Zhao B
    Cancer Res; 2017 Sep; 77(18):4868-4880. PubMed ID: 28754671
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Loss of DLG5 promotes breast cancer malignancy by inhibiting the Hippo signaling pathway.
    Liu J; Li J; Li P; Wang Y; Liang Z; Jiang Y; Li J; Feng C; Wang R; Chen H; Zhou C; Zhang J; Yang J; Liu P
    Sci Rep; 2017 Feb; 7():42125. PubMed ID: 28169360
    [TBL] [Abstract][Full Text] [Related]  

  • 26. LIFR is a breast cancer metastasis suppressor upstream of the Hippo-YAP pathway and a prognostic marker.
    Chen D; Sun Y; Wei Y; Zhang P; Rezaeian AH; Teruya-Feldstein J; Gupta S; Liang H; Lin HK; Hung MC; Ma L
    Nat Med; 2012 Oct; 18(10):1511-7. PubMed ID: 23001183
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Regulation of Hippo/YAP signaling and Esophageal Squamous Carcinoma progression by an E3 ubiquitin ligase PARK2.
    Zhou X; Li Y; Wang W; Wang S; Hou J; Zhang A; Lv B; Gao C; Yan Z; Pang D; Lu K; Ahmad NH; Wang L; Zhu J; Zhang L; Zhuang T; Li X
    Theranostics; 2020; 10(21):9443-9457. PubMed ID: 32863938
    [No Abstract]   [Full Text] [Related]  

  • 28. RASSF1A uncouples Wnt from Hippo signalling and promotes YAP mediated differentiation via p73.
    Papaspyropoulos A; Bradley L; Thapa A; Leung CY; Toskas K; Koennig D; Pefani DE; Raso C; Grou C; Hamilton G; Vlahov N; Grawenda A; Haider S; Chauhan J; Buti L; Kanapin A; Lu X; Buffa F; Dianov G; von Kriegsheim A; Matallanas D; Samsonova A; Zernicka-Goetz M; O'Neill E
    Nat Commun; 2018 Jan; 9(1):424. PubMed ID: 29382819
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Deubiquitinating Enzyme USP9X Suppresses Tumor Growth via LATS Kinase and Core Components of the Hippo Pathway.
    Toloczko A; Guo F; Yuen HF; Wen Q; Wood SA; Ong YS; Chan PY; Shaik AA; Gunaratne J; Dunne MJ; Hong W; Chan SW
    Cancer Res; 2017 Sep; 77(18):4921-4933. PubMed ID: 28720576
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Hippo pathway regulator KIBRA promotes podocyte injury by inhibiting YAP signaling and disrupting actin cytoskeletal dynamics.
    Meliambro K; Wong JS; Ray J; Calizo RC; Towne S; Cole B; El Salem F; Gordon RE; Kaufman L; He JC; Azeloglu EU; Campbell KN
    J Biol Chem; 2017 Dec; 292(51):21137-21148. PubMed ID: 28982981
    [TBL] [Abstract][Full Text] [Related]  

  • 31. LncRNA UCA1 promotes migration and invasion in pancreatic cancer cells via the Hippo pathway.
    Zhang M; Zhao Y; Zhang Y; Wang D; Gu S; Feng W; Peng W; Gong A; Xu M
    Biochim Biophys Acta Mol Basis Dis; 2018 May; 1864(5 Pt A):1770-1782. PubMed ID: 29510195
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bcl-2 dependent modulation of Hippo pathway in cancer cells.
    D'Aguanno S; Brignone M; Scalera S; Chiacchiarini M; Di Martile M; Valentini E; De Nicola F; Ricci A; Pelle F; Botti C; Maugeri-Saccà M; Del Bufalo D
    Cell Commun Signal; 2024 May; 22(1):277. PubMed ID: 38755629
    [TBL] [Abstract][Full Text] [Related]  

  • 33. IL-6 Triggers the Migration and Invasion of Oestrogen Receptor-Negative Breast Cancer Cells via Regulation of Hippo Pathways.
    Hou L; Xie S; Li G; Xiong B; Gao Y; Zhao X; Hu J; Deng S; Jiang J
    Basic Clin Pharmacol Toxicol; 2018 Nov; 123(5):549-557. PubMed ID: 29781562
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Study on mechanism about long noncoding RNA MALAT1 affecting pancreatic cancer by regulating Hippo-YAP signaling.
    Zhou Y; Shan T; Ding W; Hua Z; Shen Y; Lu Z; Chen B; Dai T
    J Cell Physiol; 2018 Aug; 233(8):5805-5814. PubMed ID: 29215734
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Platelet‑derived growth factor‑BB mediates pancreatic cancer malignancy via regulation of the Hippo/Yes‑associated protein signaling pathway.
    Li T; Guo T; Liu H; Jiang H; Wang Y
    Oncol Rep; 2021 Jan; 45(1):83-94. PubMed ID: 33416116
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibition of ERK1/2 down-regulates the Hippo/YAP signaling pathway in human NSCLC cells.
    You B; Yang YL; Xu Z; Dai Y; Liu S; Mao JH; Tetsu O; Li H; Jablons DM; You L
    Oncotarget; 2015 Feb; 6(6):4357-68. PubMed ID: 25738359
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Focal adhesion kinase (FAK) activation by estrogens involves GPER in triple-negative breast cancer cells.
    Rigiracciolo DC; Santolla MF; Lappano R; Vivacqua A; Cirillo F; Galli GR; Talia M; Muglia L; Pellegrino M; Nohata N; Di Martino MT; Maggiolini M
    J Exp Clin Cancer Res; 2019 Feb; 38(1):58. PubMed ID: 30728047
    [TBL] [Abstract][Full Text] [Related]  

  • 38. WWC2 is an independent prognostic factor and prevents invasion via Hippo signalling in hepatocellular carcinoma.
    Zhang Y; Yan S; Chen J; Gan C; Chen D; Li Y; Wen J; Kremerskothen J; Chen S; Zhang J; Cao Y
    J Cell Mol Med; 2017 Dec; 21(12):3718-3729. PubMed ID: 28815883
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Hippo Pathway Component TAZ Promotes Immune Evasion in Human Cancer through PD-L1.
    Janse van Rensburg HJ; Azad T; Ling M; Hao Y; Snetsinger B; Khanal P; Minassian LM; Graham CH; Rauh MJ; Yang X
    Cancer Res; 2018 Mar; 78(6):1457-1470. PubMed ID: 29339539
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Calmodulin activates the Hippo signaling pathway by promoting LATS1 kinase-mediated inhibitory phosphorylation of the transcriptional coactivator YAP.
    Thines L; Gorisse L; Li Z; Sayedyahossein S; Sacks DB
    J Biol Chem; 2022 May; 298(5):101839. PubMed ID: 35307353
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.